Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Li, Ming ^a   Zhang, Qian ^b   Fu, Peifang ^a   Li, Ping ^a   Peng, Aimei ^a   Zhang, Guoliang ^a   Song, Xiaolian ^a   Tan, Min ^a   Li, Xuan ^a   Liu, Yang ^a   Wu, Yueping ^a   Fan, Suyun ^a   Wang, Changhui ^a  

^a TONGJI UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GEMCITABINE; PEMETREXED; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PLATINUM DERIVATIVE;

ADVANCED CANCER; ADVANCED LUNG NON SMALL CELL CANCER; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; LUNG TUMOR; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84861217136     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037229     Document Type: Article

References (27)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Walling J, (1994) Chemotherapy for advanced non-small-cell lung cancer. Respir Med 88: 649-657.
3. Govindan R, Page N, Morgensztern D, Read W, Tierney R, et al. (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24: 4539-4544.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
5. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM, (1998) Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 38: 135-152.
6. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, et al. (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123.
7. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
8. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, et al. (2011) NCCN Practice Guidelines in Oncology: Non Small Cell Lung Cancer, version 2.2012. Available: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed: 2011 DEC 12.
9. Gronberg BH, Bremnes RM, Flotten O, Amundsen T, Brunsvig PF, et al. (2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27: 3217-3224.
10. Socinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, et al. (2010) Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 5: 1963-1969.
11. Higgins JP, Green S, (2008) Cochrane Handbook for Systematic Reviews of Interventions updated March 2011 John Wiley & Sons Available: http://www.cochrane-handbook.org/. Accessed: 2011 DEC 12.
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
13. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
15. Schulz KF, Chalmers I, Hayes RJ, Altman DG, (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408-412.
16. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
17. Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, et al. (2011) A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 6: 1907-1914.
18. Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, et al. (2009) Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14: 497-510.
19. Peterson P, Park K, Fossella F, Gatzemeier U, John W, et al. (2007) Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2: S851.
20. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, et al. (2006) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107: 1589-1596.
21. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, et al. (2008) Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 73: 1290-1300.
22. Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, et al. (2000) Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 11: 435-440.
23. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, et al. (2001) Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92: 595-600.
24. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR Jr, et al. (2005) Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104: 2449-2456.
25. Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, et al. (2011 Nov 22) Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials. Lung Cancer [Epub ahead of print].
26. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742.
27. Pao W, Kris MG, Iafrate AJ, Ladanyi M, Janne PA, et al. (2009) Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 15: 5317-5322.